New scan could clarify prostate cancer return when standard test fails

NCT ID NCT07569926

Not yet recruiting Diagnosis Sponsor: Blue Earth Diagnostics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a special PET scan using fluciclovine can help doctors decide on treatment for men whose prostate cancer has returned after initial treatment, but whose standard PSMA PET scan was unclear or negative. About 142 men will receive the fluciclovine PET scan, and researchers will track whether the results lead to a change in their treatment plan. The goal is to improve decision-making when cancer recurrence is suspected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Emory University

Atlanta, Georgia, 30322, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Oregon Health & Science University

Portland, Oregon, 97239, United States
University of California San Diego Health

San Diego, California, 92103, United States
Urology Austin

Austin, Texas, 78759, United States
Washington University

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.